Focus Partners Advisor Solutions’s Royalty Pharma RPRX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$273K	Buy	+4,671	New	+$276K	﹤0.01%	1148

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Focus Partners Advisor Solutions's RPRX Position: Q3 2026 in Review

Focus Partners Advisor Solutions opened a new position in Royalty Pharma (RPRX) in Q3 2026: 4,671 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #1148 among its holdings.

393 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Focus Partners Advisor Solutions held 4,671 shares of Royalty Pharma worth $273K as of Q3 2026.
Royalty Pharma was a new Focus Partners Advisor Solutions position in Q3 2026.
Royalty Pharma made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q3 2026, its #1148 holding.
393 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2026, filed 10 Nov 2026.